Management of Fibrosis: The Mesenchymal Stromal Cells Breakthrough

Table 6

MSC treatment on a preclinical pancreas fibrosis model.

References	Organism	Model	Treatment	MSC source	Timing	Quantity	Route	Results
[74]	Rat	DBTC	8 mg/kg DBTC injected in the tail vein	UC	5 days after DBTC injection	2.10^6 cells	Jugular vein	(i) Reduced inflammatory cell infiltration score; (ii) Reduced monocyte/macrophage infiltration; (iii) Reduced expression of MCP-1, VCAM-1, ICAM-1, IL-6, and TNF-α; (iv) Reduced fibrosis score; (v) Reduced expression of TGF-β1; (vi) Reduced concentration of collagen; (vii) Reduced number of α-SMA-positive cells

Outcomes are expressed compared to control groups (i.e., groups treated but not transplanted with MSCs) unless stated otherwise (α-SMA: α-smooth muscle actin; DBTC: dibutyltin dichloride; ICAM: intercellular adhesion molecule; IL: interleukin; MCP: monocyte chemoattractant protein; TGF-β: transforming growth factor-β; TNF-α: tumor necrosis factor-α; VCAM: vascular cell adhesion molecule).